Axsome Sinks 10% Despite Q3 Revenue Beat “Surpassing a One-Billion-Dollar Annual Run Rate”
Axsome Therapeutics (AXSM) shares fell 10% despite Q3 revenue rising 52% to $259.7M, beating consensus. Operating loss narrowed to $11.1M. FDA decision on narcolepsy drug AXS-12 is pending, competing with Jazz (JAZZ) and Alkermes (ALKS). Auvelity sales grew 53% to $207.6M, with strong prescription trends.
How this was made
The 30-second read
Why it matters
The earnings miss on operating loss and higher SG&A drove a 10% share decline, suggesting short‑term bearish pressure.
Market read
The earnings release provides fresh data that moved the stock 10% lower, offering a clear trading signal for short‑term positions.
What to watch
The upcoming FDA decision on AXS‑12 could be a catalyst for upside if the outcome is favorable.
Background
Axsome Therapeutics (AXSM) is a clinical‑stage biopharma company with products targeting neurological disorders. The Q3 earnings release included a revenue beat and higher operating expenses.
Ticker impact
Axsome Therapeutics reported Q3 revenue of $259.7M beating consensus, but shares fell 10% on the day.
likely further downside as investors price in higher expenses and await the May 1 FDA decision on AXS-12.
The stock already dropped 10% on the earnings release; no new positive catalyst was provided.
Market effects
The results highlight cost pressures in the biotech sector and may prompt scrutiny of other small-cap drug developers awaiting FDA decisions.
U.S. biotech stocks could see modest weakness as investors reassess near‑term earnings expectations.
Limited to investors focused on U.S. biotech and specialty pharma pipelines.
Counterpoint
Despite the sell‑off, the revenue beat and shrinking loss could support a short‑term bounce if the market overreacts.
Key entities
- companyAxsome Therapeutics
Biopharma firm reporting Q3 results.
- companyJazz Pharmaceuticals
Competitor mentioned in context of narcolepsy market.
- companyAlkermes
Competitor mentioned in context of narcolepsy market.
